Short-term local treatment of acute and severe non-infectious inflammatory skin diseases (dry forms), which are accompanied by persistent itching or hyperkeratosis and respond to treatment with glucocorticosteroids: seborrheic dermatitis, urticaria, atopic dermatitis, contact allergic eczema, erythema multiforme, lupus erythematosus, psoriasis of hair areas of the skin, advanced psoriasis, splashing lichen.
Flucinar ointment Composition
active substance: Fluocinolone;
1 g of ointment contains fluocinolone acetonide 0.25 mg
excipients: propylene glycol, citric acid, lanolin, white soft paraffin.
Flucinar ointment Dosage form
Basic physical and chemical properties: white or almost white, fatty soft mass, translucent, with a specific weak odor.
Flucinar ointment Pharmacotherapeutic group
Corticosteroids for dermatological use. ATX code D07A C04.
Fluocinolone acetonide is an effective synthetic GCS for external use. When used as an ointment at a concentration of 0.25 mg / g, it has a strong anti-inflammatory, antiallergic, antiallergic and vasoconstrictor effect. It has lipophilic properties and is easily absorbed through the skin. Already after applying 2 g of ointment, the production of ACTH (ACTH) by the pituitary gland may decrease as a result of inhibition of the adrenal gland-pituitary gland system.
Fluocinolone acetonide easily penetrates into the stratum corneum, where it gradually accumulates and is determined even 15 days after application. NOT metabolized in the skin. After absorption, it is systemically biotransformed mainly in the liver. It is excreted in the urine and in smaller quantities in the bile, mainly in the form of a compound with glucuronic acid, and also in small quantities unchanged.
The absorption of fluocinolone acetonide through the skin is enhanced when applied to the sensitive skin of the anatomical folds of the body and face, as well as to the skin with damaged epidermis or inflammation. The use of an occlusive dressing causes an increase in the temperature and humidity of the skin, which also leads to an increase in the absorption of fluocinolone acetonide. In addition, absorption is enhanced when the drug is used often and on large areas of the skin. Absorption through the skin is higher in adolescents than in adult patients.
Short-term treatment of acute and severe non-infectious inflammatory skin diseases (without exudation), accompanied by persistent itching or hyperkeratosis: seborrheic dermatitis, atopic dermatitis, urticaria nodosum (papular urticaria), allergic contact dermatitis, erythema multiforme, tuberculosis flatulence, volatilis squamous.
Cutaneous manifestations of syphilis, skin tuberculosis, pyoderma, chickenpox, herpes, actinomycosis, blastomycosis, sporotrichosis, diaper dermatitis, anogenital pruritus, nevus; atheroma, hemangioma, xanthoma, skin neoplasms, wounds and ulcerative lesions of the skin, wounds at the application sites, numerous psoriatic plaques, trophic ulcers associated with varicose veins, erosive and ulcerative lesions of the digestive tract.
Do not use the ointment for bacterial, viral and fungal infections of the skin, common and rosacea, perioral dermatitis (dermatitis perioralis), after prophylactic vaccinations, as well as in the case of confirmed hypersensitivity to fluocinolone acetonide or other GCS and other components of the drug.